Straits Times Index
3,322.08 -8.69 (-0.26%) S&P 500
5,360.79 +13.80 (+0.26%) Dow
38,868.04 +69.05 (+0.18%) Nasdaq
17,192.53 +59.40 (+0.35%) Bitcoin USD
69,396.90 -36.31 (-0.05%) CMC Crypto 200
1,440.18 -6.50 (-0.45%)
GILD Jul 2024 65.000 call
| Previous close | 1.5100 |
| Open | 1.2800 |
| Bid | 1.6600 |
| Ask | 1.7500 |
| Strike | 65.00 |
| Expiry date | 2024-07-19 |
| Day's range | 1.1800 - 1.6700 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.25k |
ZacksGilead Sciences (GILD) Gains As Market Dips: What You Should Know
Gilead Sciences (GILD) reachead $64.70 at the closing of the latest trading day, reflecting a +1.33% change compared to its last close.
ZacksInvestors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Business WireGilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
FOSTER CITY, Calif., June 06, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN), in adults living with compensated chronic hepatitis delta virus (HDV) infection. Published in the New England Journal of Medicine (NEJM), the data demonstrate that the investigational combination of bul
